Stockreport

FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older [Yahoo! Finance]

Ascendis Pharma A/S - American Depositary Shares  (ASND) 
Last ascendis pharma a/s - american depositary shares earnings: 11/18 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ascendispharma.com
PDF Ascendis Pharma The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing interval Commercial availab [Read more]